中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (8): 676-681.doi: 10.35541/cjd.20210751

• 论著 • 上一篇    下一篇

[开放获取] 米诺环素单药或联合小剂量糖皮质激素治疗红斑型天疱疮15例和疱疹样天疱疮9例疗效和安全性回顾分析

樊碧娆    陈喜雪    王明悦   

  1. 北京大学第一医院皮肤性病科  国家皮肤与免疫疾病临床医学研究中心  北京市皮肤病分子诊断重点实验室,北京  100034
  • 收稿日期:2021-10-14 修回日期:2022-04-29 发布日期:2022-08-02
  • 通讯作者: 王明悦 E-mail:wangmy@pku.edu.cn

Retrospective analysis of efficacy and safety of minocycline alone or in combination with low-dose glucocorticoids in the treatment of 15 cases of pemphigus erythematosus and 9 cases of pemphigus herpetiformis

Fan Birao, Chen Xixue, Wang Mingyue   

  1. Department of Dermatology and Venereology, Peking University First Hospital, National Clinical Research Center for Skin and Immune Diseases, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing 100034, China
  • Received:2021-10-14 Revised:2022-04-29 Published:2022-08-02
  • Contact: Wang Mingyue E-mail:wangmy@pku.edu.cn

摘要: 【摘要】 目的 探讨米诺环素单药或联合小剂量糖皮质激素(简称激素)治疗红斑型天疱疮(PE)和疱疹样天疱疮(PH)的疗效和安全性及对免疫指标的影响。方法 回顾性纳入2011年6月至2021年6月于北京大学第一医院皮肤科初诊、初治方案为米诺环素单独或联合小剂量激素且随访至少6个月的PE和PH患者。收集基线及不同随访时间点患者病情、自身抗体水平变化,分析疾病严重程度、诊断、自身抗体变化趋势及与疗效间的关系。采用Kaplan-Meier方法分析完全缓解情况,用卡方检验分析不同严重度和疗法下PF患者的疗效。结果 共纳入24例汉族患者,包括15例PE和9例PH,男女比例为1.4∶1,中位年龄68.8岁,中位病程为22.1个月,平均随访时间为21.8个月。24例均获得疾病控制,疾病控制时间M(Q1,Q3)为15.9(12,20.1)周。完全缓解23例 (95.8%),完全缓解时间8.7(6.4, 10)个月。米诺环素单药治疗1年完全缓解率(11/13)与联合小剂量激素疗法(9/11)差异无统计学意义(χ2 = 0.16,P = 0.692)。随访期间复发2例(8.7%),皆处于疾病控制状态,1例调整剂量后于第38周达完全缓解,另1例换用利妥昔单抗,半年后达到完全缓解。轻中度患者间疗效差异无统计学意义(χ2 = 0.28,P = 0.599)。3例发生药物相关不良反应,1例为背部体癣,2例为全身皮肤及牙龈部位色素沉着。结论 米诺环素单药或联合小剂量激素治疗轻中度PE或PH疗效显著,且无严重药物相关不良反应,但该方案的长期疗效、不良反应及患者预后需未来进一步扩大样本量,进行多中心、前瞻性研究。

关键词: 天疱疮, 治疗, 米诺环素, 糖皮质激素类, 嗜酸细胞, 中性白细胞

Abstract: 【Abstract】 Objective To investigate the efficacy and safety of minocycline alone or in combination with low-dose glucocorticoids in the treatment of pemphigus erythematosus and pemphigus herpetiformis, as well as their effect on immune indices. Methods A retrospective study was conducted, and patients with newly diagnosed pemphigus erythematosus or pemphigus herpetiformis, who received initial treatment with minocycline alone or in combination with low-dose glucocorticoids and were followed up for more than 6 months, were collected from Department of Dermatology, Peking University First Hospital from June 2011 to June 2021. Data on patients′ condition and autoantibody levels were collected at baseline and different follow-up time points, and disease severity, diagnosis, changes in autoantibody levels and their relationships with efficacy were analyzed. The Kaplan-Meier method was used to analyze complete remission rate, and chi-square test to analyze the efficacy among patients with different disease severity or after different treatments. Results A total of 24 patients of Han nationality were collected and followed up for a median period of 21.8 months, including 15 with pemphigus erythematosus and 9 with pemphigus herpetiformis. The male to female ratio was 1.4∶1, their median age was 68.8 years, and the median duration of disease was 22.1 months. All the 24 patients achieved disease control, and the time to disease control (M [Q1, Q3]) was 15.9 (12, 20.1) weeks. Twenty-three (95.8%) patients achieved complete remission, and the time to complete remission was 8.7 (6.4, 10) months. After 1-year treatment, no significant difference in the complete remission rate was observed between patients receiving minocycline monotherapy (11/13) and those receiving combination therapy with low-dose glucocorticoids (9/11, χ2 = 0.16, P = 0.692). During the follow-up period, 2 patients (8.7%) experienced recurrence in disease control state, 1 of whom achieved complete remission at week 38 after dose adjustment, and the other achieved complete remission after half-a-year treatment with rituximab. There was no significant difference in the efficacy between patients with mild and moderate pemphigus (χ2 = 0.28, P = 0.599). Drug-related adverse reactions occurred in 3 cases, including 1 case of tinea corporis on the back and 2 cases of generalized hyperpigmentation of the skin and gingiva. Conclusion Minocycline alone or in combination with low-dose glucocorticoids was effective for the treatment of mild to moderate pemphigus erythematosus and pemphigus herpetiformis without serious adverse reactions, but long-term efficacy, adverse reactions and patients′ prognosis should be re-evaluated in prospective multi-center studies with a large sample size in the future.

Key words: Pemphigus, Therapy, Minocycline, Glucocorticoids, Eosinophils, Neutrophils